Franco Ramon A, Husain Inna, Reder Lindsay, Paddle Paul
Division of Laryngology, Department of Otolaryngology, Harvard Medical School and Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, U.S.A.
Department of Otolaryngology, Rush University Medical Center, Chicago, Illinois, U.S.A.
Laryngoscope. 2018 Mar;128(3):610-617. doi: 10.1002/lary.26874. Epub 2017 Oct 8.
OBJECTIVES/HYPOTHESIS: The fibrotic/erythematous appearance of the subglottis in idiopathic subglottic stenosis (iSGS) hints that it might respond to repeated intralesional steroid treatment similar to keloids.
Retrospective cohort study.
Thirteen iSGS subjects (six treated in-office with serial intralesional steroid injections [SILSI] versus seven treated endoscopically in the operating room [OR] followed by awake SILSI) between October 2011 and April 2017. Forced spirometry was performed before injections and at each follow-up visit (peak expiratory flow [%PEF] and peak inspiratory flow). Steroids were injected via transcricothyroid or transnasal routes. Injections were grouped into rounds of four to six injections separated by 3 to 5 weeks.
Thirteen subjects with a mean follow-up of 3 years (3.3 years for SILSI and 2.7 years for OR). Awake-only SILSI subjects had a mean improvement/round of 23.1% %PEF (range, 65.4%-88.6%), whereas the OR-treated subjects had a mean %PEF improvement/round of 25.1% (range, 57.4%-82.5%). Both groups had improved breathing, and the improvements were statistically equal (P = .569). SILSI subjects underwent 5.3 injections/round in 1.3 rounds, whereas OR subjects had 5.9 injections/round over 2.1 rounds. Statistically significant improvement was seen in %PEF for both groups (SILSI P = .007, OR P = .002). Overall, SILSI achieved sustained %PEF above 80% in 83% (5/6) and OR + SILSI 86% (6/7).
SILSI in the awake outpatient setting can improve the airway caliber in iSGS and is equivalent to endoscopic OR treatment. We believe iSGS can be viewed as a chronic scarring/inflammatory condition that can benefit from steroid scar-modification therapy.
目的/假设:特发性声门下狭窄(iSGS)患者声门下的纤维化/红斑样外观提示,其可能与瘢痕疙瘩类似,对反复病灶内注射类固醇治疗有反应。
回顾性队列研究。
2011年10月至2017年4月期间的13例iSGS患者(6例在门诊接受系列病灶内类固醇注射[SILSI]治疗,7例在手术室[OR]接受内镜治疗,随后接受清醒状态下SILSI治疗)。在注射前及每次随访时进行用力肺活量测定(呼气峰值流速[PEF%]和吸气峰值流速)。类固醇通过经环甲膜或经鼻途径注射。注射分为每轮4至6次,间隔3至5周。
13例患者平均随访3年(SILSI组为3.3年,OR组为2.7年)。仅接受清醒状态下SILSI治疗的患者平均每轮PEF改善23.1%(范围为65.4% - 88.6%),而接受OR治疗的患者平均每轮PEF改善25.1%(范围为57.4% - 82.5%)。两组患者呼吸均有改善,且改善程度在统计学上无差异(P = 0.569)。SILSI组患者每轮接受5.3次注射,共1.3轮,而OR组患者每轮接受5.9次注射,共2.1轮。两组患者的PEF%均有统计学意义的改善(SILSI组P = 0.007,OR组P = 0.002)。总体而言,SILSI组83%(5/6)的患者PEF持续维持在80%以上,OR + SILSI组为86%(6/7)。
门诊清醒状态下的SILSI可改善iSGS患者的气道管径,且与内镜OR治疗效果相当。我们认为iSGS可被视为一种慢性瘢痕形成/炎症性疾病,可从类固醇瘢痕修饰治疗中获益。
4。《喉镜》,2018年,第128卷,第610 - 617页。